<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164750">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953173</url>
  </required_header>
  <id_info>
    <org_study_id>HERO Study</org_study_id>
    <nct_id>NCT00953173</nct_id>
  </id_info>
  <brief_title>HERO Study: Helping Evaluate Reduction in Obesity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apollo Endosurgery, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apollo Endosurgery, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, international, multi-center study of clinical outcomes and estimated
      healthcare resource expenditures associated with the treatment of obesity using the LAP-BAND
      AP® Adjustable Gastric Banding System.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight, waist and hip circumference, blood pressure, HbA1c, fasting glucose, lipid profile, concomitant medications, and health-related quality of life (HRQOL)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1106</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>LapBand</arm_group_label>
    <description>Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAP-BAND AP® Adjustable Gastric Banding System</intervention_name>
    <description>The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.</description>
    <arm_group_label>LapBand</arm_group_label>
    <other_name>LAP-BAND AP®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have already made a decision, independent of the study, to proceed with
        LAP-BAND AP® implantation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient and investigator have made a decision, independent of the study, to proceed
             with LAP-BAND AP® implantation.

          -  Male or female aged ≥ 18 years.

          -  BMI ≥ 40 or a BMI ≥ 35 with one or more severe co-morbid conditions, or those who are
             45.5 Kg / 100 lbs or more over their estimated ideal weight.

        Exclusion Criteria:

          -  Prior bariatric surgery.

          -  Type I diabetes patients.

          -  Participating in another ongoing clinical study with concomitant diagnostic or
             therapeutic intervention that would reasonably be expected to alter patterns of care,
             use of medications or the outcomes under study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>August 5, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
